A study testing whether a GLP-1 medicine, semaglutide, can help people lose weight.

Recruiting now. Registry record last updated July 27, 2026.

Who can join: Adults 18 to 65, have obesity or are overweight, BMI 30+.
What you take: semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The study runs about 11 months.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 4Sponsor Gila Therapeutics, Inc.Drug semaglutideClass GLP-1 RASites 1 USEnrollment target 40

What this study is for

Primary condition: Obesity & Overweight.

Full scientific study title: A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity.

Who can join

Age18 to 65SexAnyBMI30 to 45

Adults 18 to 65, have obesity or are overweight, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Body Mass Index 30 to 45

Key exclusion criteria

Type 2 Diabetes Mellitus
Multiple Endocrine Neoplasia Type 2
Medullary thyroid cancer

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Minnesota1 site

Clinical Research Institute of Minnesota
Minneapolis, Minnesota
Gary D Berman, M.D.612-333-2200gdb@allergy-asthma-docs.com

Follow this trial

We email you if NCT07728383 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: June 17, 2026. Expected completion: May 2027. Last updated on ClinicalTrials.gov: July 27, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 29, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.